Kerrii B. Anderson Sells 1,000 Shares of Laboratory Co. of America Holdings (NYSE:LH) Stock

Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $230.00, for a total transaction of $230,000.00. Following the completion of the sale, the director now owns 13,722 shares of the company’s stock, valued at $3,156,060. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Laboratory Co. of America Trading Down 0.6 %

NYSE:LH opened at $228.63 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.77 and a current ratio of 0.88. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $239.50. The stock has a market cap of $19.27 billion, a P/E ratio of 46.00, a P/E/G ratio of 1.70 and a beta of 1.05. The stock has a 50-day simple moving average of $222.60 and a 200-day simple moving average of $212.44.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.02. Laboratory Co. of America had a return on equity of 15.39% and a net margin of 3.60%. The firm had revenue of $3.28 billion during the quarter, compared to the consensus estimate of $3.26 billion. During the same period in the prior year, the company posted $3.38 earnings per share. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. As a group, analysts anticipate that Laboratory Co. of America Holdings will post 14.55 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be paid a $0.72 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $2.88 annualized dividend and a yield of 1.26%. Laboratory Co. of America’s payout ratio is currently 57.95%.

Analysts Set New Price Targets

LH has been the topic of several research analyst reports. UBS Group boosted their price objective on Laboratory Co. of America from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, August 2nd. StockNews.com lowered shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a research note on Friday. Barclays lifted their price objective on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the company an “equal weight” rating in a report on Friday. Bank of America increased their target price on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “buy” rating in a report on Monday, August 5th. Finally, Jefferies Financial Group boosted their price target on shares of Laboratory Co. of America from $245.00 to $265.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Five investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.54.

Institutional Trading of Laboratory Co. of America

A number of hedge funds have recently added to or reduced their stakes in LH. Industrial Alliance Investment Management Inc. acquired a new position in shares of Laboratory Co. of America during the 2nd quarter valued at about $27,000. Horizon Bancorp Inc. IN purchased a new position in Laboratory Co. of America during the third quarter worth approximately $29,000. Pathway Financial Advisers LLC acquired a new position in shares of Laboratory Co. of America in the 1st quarter valued at $30,000. Innealta Capital LLC purchased a new stake in shares of Laboratory Co. of America during the 2nd quarter valued at $32,000. Finally, Family Firm Inc. acquired a new stake in shares of Laboratory Co. of America during the 2nd quarter worth $37,000. 95.94% of the stock is owned by institutional investors and hedge funds.

Laboratory Co. of America Company Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.